Labcorp Holdings (LH) shares inched up about 1% today, adding to their steady gains over the past month. With recent momentum continuing, investors are considering what factors could drive further moves in the healthcare giant’s stock.

See our latest analysis for Labcorp Holdings.

Labcorp Holdings has delivered a robust run this year, with the share price rallying more than 25% year to date and momentum accelerating over the past quarter. Investors have seen an impressive 34% total shareholder return for the past 12 months, and the company's multi-year results point toward sustained long-term gains. This signals that market sentiment around future growth remains upbeat.

If you’re searching for more healthcare names with strong momentum and upside potential, explore our full list of opportunities here: See the full list for free.

But with shares nearing analyst price targets and robust gains already recorded, investors have to ask whether Labcorp is trading below its true value or if the strong outlook has already been fully priced in.

With Labcorp Holdings closing at $285.94 and the most popular narrative setting fair value at $296.18, the stock sits just below its projected worth. This slender margin highlights nuanced expectations driving the outlook, so let's look at what underpins this valuation.

Labcorp's strategic collaborations and acquisitions, such as with Inspira Health and BioReference Health, are expected to drive revenue growth by expanding its presence in high-growth therapeutic areas like oncology and strengthening partnerships with health systems. The introduction of innovative tests in oncology, women's health, autoimmune disease, and neurology is anticipated to capture more test volume and outpace growth in the broader market, positively impacting revenue and earnings.

Read the complete narrative.

Want to know the logic hidden behind this ambitious target? The narrative’s bold projections hinge on a future-shaping product pipeline and aggressive margin expansion. Curious what assumptions push valuation above today’s price? Click through to uncover the specific financial leaps this scenario depends on.

Result: Fair Value of $296.18 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, regulatory changes and competitive pressures could challenge Labcorp's growth story. These factors could potentially alter the outlook behind even the most optimistic forecasts.

Find out about the key risks to this Labcorp Holdings narrative.

Taking a fresh look with the SWS DCF model, Labcorp is estimated to be trading almost 50% below its fair value. This result suggests a far larger margin for upside compared to the multiples-based view. Can simple earnings explain it all, or is the market missing deeper value?

Look into how the SWS DCF model arrives at its fair value.

If you want to see the story from a different angle or trust your own research, you can easily explore the data and build a narrative yourself in just a few minutes: Do it your way

A great starting point for your Labcorp Holdings research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.

Take charge of your next move with smart growth, future trends, and reliable opportunities by checking out these hand-picked lists below. Miss them, and you might skip tomorrow’s top performers.

Earn consistent income by tapping into reliable yield with 3%;elm:context_link;itc:0;sec:content-canvas\\" class=\\"link \\">these 18 dividend stocks with yields > 3% for stocks with dividends over 3%.

Ride the next big wave and catch leading innovators across artificial intelligence through these 24 AI penny stocks before the crowd notices.

Stay ahead of the curve and find under-the-radar winners with proven upside using these 871 undervalued stocks based on cash flows that trade well below their cash flow potential.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include LH.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com